Advocacy Archives – Page 10 of 11 – Treatment Action Group

Treatment Action Group Celebrates New Guidance on the Right to Science by Global Human Rights Body

April 14, 2020
Dorrit Walsh

Treatment Action Group (TAG) celebrates publication of the General Comment on “the human right of everyone to participate in and to enjoy the benefits of scientific progress and its applications” (the right to science), and calls the attention of grassroots activists and global civil society working on health to this landmark document.

TAG Statement on WHO Updated TB Preventive Therapy Guidance

March 31, 2020
Dorrit Walsh

Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).

Treatment Action Group Statement on the High Price of Cepheid’s Xpert Test for COVID-19

March 27, 2020
Dorrit Walsh

Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of…

Science-Based Activism to End Epidemics, from AIDS to COVID-19

March 25, 2020
Dorrit Walsh

We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.

African Declaration to Eliminate Hepatitis C and Improve the Health of People Who Use Drugs

February 20, 2020
Dorrit Walsh

A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.

TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of Low-Cost PrEP

November 11, 2019
Dorrit Walsh

Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.

Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5

October 31, 2019
Dorrit Walsh

The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy

October 31, 2019
Dorrit Walsh

October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…

Activist Guide to Hepatitis C Virus Diagnostics

October 31, 2019
Chad Cipiti

The purpose of this new publication is to provide information for you and your community. The Activist Guide aims to provide a deeper focus on diagnosis with updated information about the steps and different technologies involved in diagnosing a person with hepatitis C.

Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson

October 31, 2019
Dorrit Walsh

Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.